Loading...
Printed on 6/3/2026
For informational purposes only. This is not medical advice.
APRI is a non-invasive fibrosis marker that combines AST elevation relative to lab ULN and thrombocytopenia signal from platelet count. It is commonly used in chronic hepatitis and broader fibrosis triage pathways.
Formula: APRI = ((AST / AST ULN) x 100) / Platelets
Create an account to save calculations, favorite tools, and access your dashboard anytime.
Already have an account? Sign in
Higher APRI values generally indicate greater fibrosis likelihood, while lower values suggest lower probability of advanced fibrosis.
Use APRI for non-invasive fibrosis risk stratification when AST and platelets are available, especially in initial hepatology triage.
APRI can be distorted by acute hepatitis flares, lab-specific AST ULN definitions, and non-hepatic causes of thrombocytopenia.
For related assessments, see FIB-4, AST/ALT Ratio and MELD Score.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Estimate liver fibrosis risk using age, AST, ALT, and platelet count with the FIB-4 index.
GastroenterologyCalculate the AST/ALT ratio as an adjunct liver injury pattern marker in hepatology evaluation.
ClinicalCalculate the MELD and MELD-Na scores to assess liver disease severity and transplant priority. Uses bilirubin, INR, creatinine, and sodium.
ClinicalCalculate the Child-Pugh score to classify the severity of chronic liver disease and estimate prognosis. Uses bilirubin, albumin, INR, ascites, and encephalopathy.